The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Clinical Cancer Research|2021Cited by 44
Abstract CT028: First-in-human phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanismsSarah P. Blagden, Essam Ghazaly, Michaela Serpi et al.|Cancer Research|2016Cited by 5
Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738Hagen Schwenzer, Sarah P. Blagden, Mary Kudsy et al.|Cancer Research|2021Cited by 1
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Unknown|2024Cited by 0